SpineX

Executive Summary

SpineX is a private medical bioelectric solutions company based in Los Angeles, developing non-invasive neuromodulation therapies for urologic and neurologic conditions. Its lead program targets neurogenic bladder (NB) in patients with spinal cord injury or multiple sclerosis, aiming to restore bladder function via a proprietary non-invasive electrical stimulation platform. The company is also advancing a technology for cerebral palsy (CP), addressing underlying neural deficits rather than symptoms alone. Founded in 2018, SpineX operates in the large and growing neurostimulation market, with NB affecting over 1 million Americans and CP being the most common motor disability in children. Its non-invasive approach could offer a safer, more accessible alternative to surgical implants or catheterization, potentially transforming standard of care. Preclinical and early clinical data have shown promise in improving bladder capacity and reducing incontinence episodes, while the CP program has demonstrated motor function improvements in early studies. The company is actively seeking regulatory clearances and clinical partnerships to validate its technology in larger trials.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for neurogenic bladder device60% success
• Q4 2026Top-line results from pivotal clinical trial for neurogenic bladder55% success
• Q1 2027Strategic partnership or licensing deal for cerebral palsy program40% success